Project Grant R44DK115301

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate a novel adipokine as a potential therapeutic approach for resolving non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The total award amount is $469,235 and the project period runs from September 1, 2024 to June 30, 2028. The University of...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $293,543 to Furanica, Inc. to develop a novel compound, FAL-113, for the treatment of nonalcoholic steatohepatitis (NASH). The project aims to determine the mechanism of action, pharmacokinetics, and pharmacological efficacy of FAL-113 in preclinical NASH models. FAL-113 is designed to simultaneously modulate...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of novel small molecule modulators called Parmodulins to treat metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). The $1,391,142 award to Function Therapeutics Inc. will fund research to synthesize and profile...

The U.S. Department of Health and Human Services' National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $361,400 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Oncotrap Inc. The funding supports the development of a bispecific single-domain antibody targeting the chemokines CCL2 and CCL5 for the treatment of non-alcoholic steatohepatitis (NASH). The award will enable Oncotrap to generate a human version...

This $499,774 cooperative agreement from the Department of Health and Human Services' Food and Drug Administration will support the University of California, San Diego in qualifying composite quantitative imaging biomarkers for diagnostic enrichment in nonalcoholic steatohepatitis (NASH) clinical trials. Over the one-year period from September 1, 2022 to August 31, 2023, UC San Diego will prepare and submit a biomarker qualification plan to the FDA's Center for Drug Evaluation and Research...

This $707,389 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to evaluate the evolution of nonalcoholic fatty liver disease (NAFLD) during pregnancy and its influence on pregnancy outcomes. The study, titled "TARGETING NONALCOHOLIC FATTY LIVER DISEASE DURING THE REPRODUCTIVE PERIOD TO IMPROVE WOMEN'S HEALTH OUTCOMES,"...

This federal Project Grant award of $806,452 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to investigate the mechanisms that combine type 2 diabetes (T2D) with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The research, led by The Children's Hospital Corporation (doing business as Boston Children's Hospital),...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research, supports Faknostics LLC's research into novel peptide-based inhibitors targeting the paxillin-FAK interaction as a potential treatment for liver fibrosis. The $651,952 award will enable Faknostics to optimize lead peptide candidates, characterize their biophysical and biochemical activity, and confirm...

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to understand the role of the unfolded protein response (UPR) in the development of non-alcoholic steatohepatitis (NASH), a leading cause of liver transplantation. The $172,060 award, granted on January 9, 2025, aims to elucidate the mechanisms by which the loss of the...

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is funding research to define the role of antigen-specific T cell responses in non-alcoholic steatohepatitis (NASH). The $599,541 award, made on Sep 15, 2024, with a completion date of Aug 31, 2025, aims to: (1) determine the timing of T cell clonal expansion during NASH progression; (2)...